Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Tuesday,RTT News reports.

A number of other research analysts have also recently issued reports on the stock. Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $198.00 to $370.00 in a research note on Friday, August 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ ALNY opened at $247.05 on Tuesday. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a market cap of $31.86 billion, a PE ratio of -94.29 and a beta of 0.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a 50-day moving average of $273.54 and a two-hundred day moving average of $236.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the company posted $1.15 earnings per share. The company’s revenue was down 33.3% on a year-over-year basis. As a group, equities analysts expect that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALNY. Teachers Retirement System of The State of Kentucky increased its holdings in Alnylam Pharmaceuticals by 4.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock valued at $9,547,000 after buying an additional 1,500 shares in the last quarter. Toronto Dominion Bank boosted its position in Alnylam Pharmaceuticals by 27.3% during the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock worth $4,254,000 after acquiring an additional 3,315 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in Alnylam Pharmaceuticals by 43.7% during the third quarter. Coldstream Capital Management Inc. now owns 1,211 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 368 shares during the last quarter. Geode Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after acquiring an additional 66,928 shares during the last quarter. Finally, Prestige Wealth Management Group LLC raised its stake in Alnylam Pharmaceuticals by 65.8% during the third quarter. Prestige Wealth Management Group LLC now owns 451 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 179 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.